David Brabham
Impact in
-
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Internal Medicine top 10%
Papers in
-
- Venous Thromboembolism Diagnosis and Management 2
-
- Cardiovascular Function and Risk Factors 1
- Co-authors
- Muhammad Atif Khan (1 shared paper)
- Journals
- Circulation (3 papers)Journal of the American College of Cardiology (2 papers)JAMA (1 paper)JAMA Network Open (1 paper)Diabetes Care (1 paper)
- Partner nations
- United StatesPakistan
In The Last Decade
David Brabham
14 papers receiving 782 citations
David Brabham's Hit Papers
Peers
Comparison fields: 5 of 60
- Cardiology and Cardiovascular Medicine 260
- Internal Medicine 35
- Surgery 406
- Endocrinology, Diabetes and Metabolism 133
- Genetics 83
Countries citing papers authored by David Brabham
This map shows the geographic impact of David Brabham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Brabham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Brabham more than expected).
Fields of papers citing papers by David Brabham
This network shows the impact of papers produced by David Brabham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Brabham. The network helps show where David Brabham may publish in the future.
Co-authors
The 1 scholars most cited alongside David Brabham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial Hit paper breakdown → | 2019 | 239 |
| 2 | 2019 | 159 | |
| 3 | 2022 | 122 | |
| 4 | 2021 | 114 | |
| 5 | 2022 | 78 | |
| 6 | 2021 | 28 | |
| 7 | 2025 | 18 | |
| 8 | 2025 | 16 | |
| 9 | 2022 | 15 | |
| 10 | 2024 | 15 | |
| 11 | 2021 | 11 | |
| 12 | 2019 | 8 | |
| 13 | 2023 | 1 | |
| 14 | 2019 | 1 | |
| 15 | 2023 | 0 |
About David Brabham
David Brabham is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine, Surgery, Toxicology and Critical Care and Intensive Care Medicine, having authored 15 papers that have together received 825 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (5 papers), Venous Thromboembolism Diagnosis and Management (2 papers), Cannabis and Cannabinoid Research (1 paper), Forensic Toxicology and Drug Analysis (1 paper), Infective Endocarditis Diagnosis and Management (1 paper), Poisoning and overdose treatments (1 paper), Cardiovascular Function and Risk Factors (1 paper) and Diabetes, Cardiovascular Risks, and Lipoproteins (1 paper). The work is most often cited by research in Cardiology and Cardiovascular Medicine (260 citations), Internal Medicine (35 citations), Surgery (406 citations), Endocrinology, Diabetes and Metabolism (133 citations) and Genetics (83 citations). David Brabham has collaborated with scholars based in United States and Pakistan. Frequent co-authors include Muhammad Atif Khan. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, JAMA, JAMA Network Open and Diabetes Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.